These sources offer a comprehensive overview of accessing GLP-1 medications for individuals in the United States who rely on Medicaid and Medicare. 

The Centers for Medicare & Medicaid Services said this week it did not move forward with a proposal put forth by the Biden administration for Medicare coverage of weight-loss drugs such as Novo Nordisk's Wegovy.

They highlight the complexities of coverage, which often differs based on the medication's approved use (diabetes vs. weight loss) and the specific state or Medicare plan. The texts explore alternative pathways for obtaining these costly drugs, such as patient assistance programs and state initiatives. Furthermore, they discuss the crucial role of advocacy groups and potential future policy changes that could broaden access. Finally, the sources provide practical tips for beneficiaries navigating insurance requirements, prior authorizations, and appeals processes.

This is the official podcast of GLP-1 Tribe.  Find all the best resources about GLP-1 on the GLP-1 Tribe web site.
https://glp1tribe.com/